Literature DB >> 33722205

Phenylketonuria and juvenile idiopathic arthritis: a case report.

Ting Ting Zhu1,2, Jin Wu1,2, Li Yuan Wang3,4, Xiao Mei Sun5,6.   

Abstract

BACKGROUND: Phenylketonuria (PKU) is a genetic metabolic disorder in which patients have no ability to convert phenylalanine to tyrosine. Several autoimmune diseases have been reported to combine with PKU, co-existent of PKU and Juvenile Idiopathic Arthritis (JIA) has not been presented. CASE
PRESENTATION: The girl was diagnosed with PKU at the age of 1 month confirmed by molecular data. At the age of 3.5 years, she presented with pain and swelling of her right ankle, right knee, and right hip joint. After a serial of examinations, she was diagnosed with JIA and treated with a nonsteroidal anti-inflammatory drug.
CONCLUSIONS: We report a rare case of a 4-year-old girl with PKU and JIA, which supports a possible interaction between PKU and JIA. Long-term metabolic disturbance may increase the susceptibility to JIA. Further chronic inflammation could alter the metabolism of tryptophan and tyrosine to increase blood Phe concentration. In addition, corticosteroid and methotrexate therapy for JIA may increase blood Phe concentration.

Entities:  

Keywords:  Inflammation; Juvenile idiopathic Arthritis; Phenylketonuria

Year:  2021        PMID: 33722205      PMCID: PMC7962320          DOI: 10.1186/s12887-021-02602-6

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.125


  6 in total

1.  Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms.

Authors:  Lucile Capuron; Sebastian Schroecksnadel; Catherine Féart; Agnès Aubert; Denise Higueret; Pascale Barberger-Gateau; Sophie Layé; Dietmar Fuchs
Journal:  Biol Psychiatry       Date:  2011-01-31       Impact factor: 13.382

Review 2.  Phenylketonuria.

Authors:  Nenad Blau; Francjan J van Spronsen; Harvey L Levy
Journal:  Lancet       Date:  2010-10-23       Impact factor: 79.321

3.  Pathogenic implications of age of onset in juvenile rheumatoid arthritis.

Authors:  D B Sullivan; J T Cassidy; R E Petty
Journal:  Arthritis Rheum       Date:  1975 May-Jun

4.  The challenges of managing coexistent disorders with phenylketonuria: 30 cases.

Authors:  A MacDonald; K Ahring; M F Almeida; A Belanger-Quintana; N Blau; A Burlina; M Cleary; T Coskum; K Dokoupil; S Evans; F Feillet; M Giżewska; H Gokmen Ozel; A S Lotz-Havla; E Kamieńska; F Maillot; A M Lammardo; A C Muntau; A Puchwein-Schwepcke; M Robert; J C Rocha; S Santra; R Skeath; K Strączek; F K Trefz; E van Dam; M van Rijn; F van Spronsen; S Vijay
Journal:  Mol Genet Metab       Date:  2015-10-09       Impact factor: 4.797

Review 5.  Metabolism of glycosaminoglycans in the course of juvenile idiopathic arthritis.

Authors:  Katarzyna Winsz-Szczotka; Łukasz Mencner; Krystyna Olczyk
Journal:  Postepy Hig Med Dosw (Online)       Date:  2016-03-04       Impact factor: 0.270

6.  Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression.

Authors:  Gerdien A H Korte-Bouws; Eline Albers; Marije Voskamp; Hendrikus Hendriksen; Lidewij R de Leeuw; Onur Güntürkün; Sytze de Roock; Sebastiaan J Vastert; S Mechiel Korte
Journal:  Pharmaceuticals (Basel)       Date:  2019-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.